| |
Wednesday, August 7, 2024 | 10am ET / 7am PT Demand for safe, cost-effective RNA manufacturing is increasing. Knowing how to effectively streamline processes and choose the right partners are critical to success. Join us as we explore the latest strategies and solutions to meet today’s increasing demands for safety and cost-effectiveness. Register now.
|
|
Today’s Big NewsJul 25, 2024 |
| By Nick Paul Taylor Roche has punted a Pompe disease gene therapy from its pipeline after weighing up the competitive landscape. The Swiss drugmaker made the change in a second-quarter update that also featured news of TIGIT trial closures and a commitment not to make “huge cuts” to the organization. |
|
|
|
By Angus Liu Among AstraZeneca's growth drivers with $5 billion or more in peak sales potential, the company is counting on Daiichi Sankyo-partnered Enhertu to chart new territory. And stalling sales underscore the challenges facing the HER2 drug. |
By Conor Hale Edwards will gain JenaValve's transcatheter aortic regurgitation valve and Endotronix's implantable heart failure monitor, as it plans for slower TAVR sales in 2024. |
By Fraiser Kansteiner Following last week’s R&D day, argenx continues to demonstrate that its flagship drug, FcRn inhibitor Vyvgart, has plenty of room to grow in its inaugural generalized myasthenia gravis (gMG) indication. |
|
September 25-27, 2024 | Philadelphia, PA Join the Fierce Clinical Summit, the premier event for clinical research and trial management. Explore topics in Clinical Operations, Quality, and DCT & Technology. Learn, network, and connect with peers to advance industry standards and innovations in clinical trials. Secure your pass today!
|
|
By Gabrielle Masson AbbVie is discontinuing solo development of a midstage Alzheimer’s disease candidate, a monoclonal antibody that failed to differentiate itself against already approved treatments. |
By Zoey Becker The company's first gene therapy will debut in Europe as Durveqtix. In the U.S., the drug is approved under the brand name Beqvez. |
By Darren Incorvaia Charles Baum, M.D., Ph.D., who oversaw Mirati's $5.8 billion sale to Bristol Myers Squibb last year, is taking the helm of Terremoto Biosciences. |
By Annalee Armstrong Viking Therapeutics will launch a longship into phase 3 for the obesity drug VK2735 sooner than expected, with a clinical program expected to top $300 million. |
By Kevin Dunleavy While Roche touted sales and market share increases for eye disease drug Vabysmo on Thursday, there is evidence of a slowdown of its momentum as it battles Regeneron and Bayer’s powerhouse Eylea. |
By Nick Paul Taylor Emergent BioSolutions is mounting another ad blitz, teaming up again with the former NFL star Emmitt Smith to get the message out about how to use Narcan to tackle opioid overdoses. |
By Conor Hale According to the company, it has launched a voluntary correction effort after internal testing found issues with three lots of the devices. |
By Zoey Becker Skyrizi's recent ulcerative colitis nod sets it up as a first-line option, while Rinvoq is poised to handle later lines. |
By Gabrielle Masson,Darren Incorvaia,Max Bayer We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking biopharma layoffs. |
By Andrea Park Northwell Health is rolling out the red carpet for its latest venture, a film studio it’ll use to advance its brand storytelling work. |
Fierce podcastsDon’t miss an episode |
| In February, Novo Holdings announced a $16.5 billion deal to acquire Catalent, and this week on "The Top Line," we explore the current state and implications of the proposed buyout. |
|
|---|
|
|
|
Wednesday, September 11, 2024 | 2pm ET / 11am PT As the drug development landscape rapidly evolves, artificial intelligence (AI) is emerging as a transformative force, fundamentally reshaping processes and enhancing efficiencies. Join us for a deep dive into AI’s significant impact on streamlining clinical project management, revolutionizing the generation of crucial research outputs and accelerating drug discovery. Register now.
|
|
| WhitepaperDownload the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale. Sponsored by: Thermo Fisher Scientific |
| WhitepaperIn this white paper, Lonza experts delve into the common challenges encountered by ADC developers. They explore new drug product capabilities in relation to cytotoxic drug development and manufacturing, therefore fully completing Lonza’s integrated ADC offering. Further, they discuss how this end-to-end approach can significantly accelerate the timeline to investigational new drug filing and beyond. Read this white paper to learn more. Sponsored by: Lonza |
| WhitepaperThe definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
| WhitepaperIn a complex industry like biopharma, being a “Best Practice Organization” (BPO) is essential to success. But what is a BPO & how do you build one? This eBook provides the answers. Sponsored by: Blue Matter, strategic consultants in the life sciences |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
